Cansino Biologics Stock Performance
| CASBF Stock | USD 4.47 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.42, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning CanSino Biologics are expected to decrease at a much lower rate. During the bear market, CanSino Biologics is likely to outperform the market. At this point, CanSino Biologics has a negative expected return of -0.33%. Please make sure to confirm CanSino Biologics' maximum drawdown, as well as the relationship between the kurtosis and day typical price , to decide if CanSino Biologics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days CanSino Biologics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's fundamental drivers remain nearly stable which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 4.4 B | |
| Total Cashflows From Investing Activities | -2.6 B |
CanSino |
CanSino Biologics Relative Risk vs. Return Landscape
If you would invest 560.00 in CanSino Biologics on November 10, 2025 and sell it today you would lose (113.00) from holding CanSino Biologics or give up 20.18% of portfolio value over 90 days. CanSino Biologics is currently producing negative expected returns and takes up 2.6616% volatility of returns over 90 trading days. Put another way, 23% of traded pink sheets are less volatile than CanSino, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
CanSino Biologics Target Price Odds to finish over Current Price
The tendency of CanSino Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.47 | 90 days | 4.47 | about 77.04 |
Based on a normal probability distribution, the odds of CanSino Biologics to move above the current price in 90 days from now is about 77.04 (This CanSino Biologics probability density function shows the probability of CanSino Pink Sheet to fall within a particular range of prices over 90 days) .
CanSino Biologics Price Density |
| Price |
Predictive Modules for CanSino Biologics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as CanSino Biologics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.CanSino Biologics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. CanSino Biologics is not an exception. The market had few large corrections towards the CanSino Biologics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold CanSino Biologics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of CanSino Biologics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.28 | |
β | Beta against Dow Jones | -0.42 | |
σ | Overall volatility | 0.50 | |
Ir | Information ratio | -0.15 |
CanSino Biologics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of CanSino Biologics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for CanSino Biologics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| CanSino Biologics generated a negative expected return over the last 90 days | |
| About 27.0% of the company shares are held by company insiders |
CanSino Biologics Fundamentals Growth
CanSino Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CanSino Biologics, and CanSino Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CanSino Pink Sheet performance.
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 3.58 B | |||
| Shares Outstanding | 114.78 M | |||
| Price To Earning | 19.25 X | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 2.51 X | |||
| Revenue | 4.3 B | |||
| EBITDA | 2.05 B | |||
| Cash And Equivalents | 7 B | |||
| Cash Per Share | 28.36 X | |||
| Total Debt | 40 M | |||
| Debt To Equity | 0.26 % | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.59 X | |||
| Total Asset | 11.87 B | |||
About CanSino Biologics Performance
By analyzing CanSino Biologics' fundamental ratios, stakeholders can gain valuable insights into CanSino Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CanSino Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CanSino Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2191 people.Things to note about CanSino Biologics performance evaluation
Checking the ongoing alerts about CanSino Biologics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CanSino Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CanSino Biologics generated a negative expected return over the last 90 days | |
| About 27.0% of the company shares are held by company insiders |
- Analyzing CanSino Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CanSino Biologics' stock is overvalued or undervalued compared to its peers.
- Examining CanSino Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CanSino Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CanSino Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CanSino Biologics' pink sheet. These opinions can provide insight into CanSino Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CanSino Pink Sheet analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |